News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
5
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
82
|
|
Created
|
04/13/10
|
Type
|
Free
|
| Moderators | |||
Lescarden Inc. (LCAR)
Lescarden Inc/Catrix® is a biotechnology company dedicated to the development of natural, biologic therapies for burn and chronic wound management, clinical skin care, osteoarthritis and immune system applications.
Soon to be the #1 Penny Stock in America
Lescarden (LCAR) is a small biotech company that is a leader in the $17 BILLION Wound Care sector. Their lead product, Catrix is patented and has been approved by the EU and the FDA to treat chronic wounds, severe burns and multiple other applications!
Clinical and laboratory studies also point to Catrix as a potential agent for the treatment of certain cancers!
Lescarden (LCAR) is now believed to be in buyout discussions with British based BIG PHARMA Smith and Nephew who have operations in over 100 countries!
Smith and Nephew is one of the leading BIG PHARMA's investing in acquiring small Wound Care biotechs, and have already signed a licensing agreement with Lescarden (LCAR) for the distribution of Catrix in the Spain!
Lescarden (LCAR) also has signed an exclusive license agreement with Daewoong Pharmaceuticals, headquartered in Seoul, South Korea. Daewoong is the largest producer and marketer of over-the counter and ethical pharmaceutical products in Korea, with annual sales over $400 million. Already established in the diabetic foot ulcer segment of the market, Daewoong is expanding its product line to cover all aspects of wound treatment. This brings added value to any acquisition discussions with Smith and Nephew who would then increase their footprint in Asia!
Right now the hottest merger and acquisition sector in the biotech industry is Wound Care and the buyout rate of small biotech companies specializing in Wound Care is forecast to increase in 2017. The global market for Wound Care is projected to top $20 BILLION by 2021!
Lescarden (LCAR) already has a huge edge over many competitors, it has gone from FDA and EU approval to commercializing Catrix and has begun to set record revenues.
For the nine months ended February 28, 2017 compared to February 28, 2016 revenues increased by 270% approaching half a million dollars. Sales would have been even higher but supply issues led to the delayed shipment of Catrix to Smith and Nephew!
Lescarden (LCAR), trading at 2 cents a share is going to get snapped up! Just read below all the buyouts and acquisitions that have been occurring in the previously overlooked wound care sector!
LCAR's Catrix is an amazing product, when applied directly to non-healing wounds, such as debubitus ulcers (bedsores), diabetic ulcers, and venous ulcers, Catrix Wound Dressing actually accelerates the healing process, effectively closing the wounds while minimizing scarring.
In studies performed on wounds that had previously failed to respond to months of standard wound healing treatment, dramatic improvements were seen in just seven weeks!
BUT IT GETS EVEN BETTER
Clinical and laboratory studies also point to Catrix as a potential agent for the treatment of certain cancers!
Lescarden (LCAR) also has 2 other products that have been commercialized:
-Poly-NAG in the anti-arthritic market as a treatment for osteoarthritis. Clinical trials were so successful that both the US and EU awarded patents to Lescarden (LCAR)! This is a huge market with North American sales of anti-arthritic remedies are over $400 million annually.
-Bio-Cartilage, a pure Bovine Tracheal Cartilage supplement used for the potential treatment for certain types of cancer, Inflammatory Joint Disease and as a immune system enhancer.
Lescarden (LCAR) is EXTREMELY UNDERVALUED, trading near historic lows around 2 cents a share and UNDER THE RADAR!
Now is the time to BUY shares of Lescarden (LCAR)
LCAR has a tiny share structure with only 63M O/S of which INSIDERS own 22M, the float is a mere 16M shares.
(This means that the share price could rise very quickly with limited shares available!)
WOUND CARE is now HUGE business for pharmaceutical companies!
What makes Lescarden Inc. (LCAR) so attractive is that big pharmaceutical companies have until recently overlooked the wound care market. In the last few years a spate of buyouts and acquisitions has begun as BIG PHARMAS start to scoop up smaller players.
NOW is the time to buy shares of tiny LCAR, they will be acquired by the end of 2017!
JUST LOOK AT THESES HEADLINE CLIPS:
Overlooked Advanced Wound Care Market Catches Attention of Healthcare Analysts, Investors
Predictably, several healthcare analysts and some savvy investors have started paying attention to this niche market.
There are about 50 million reported cases globally of patients suffering from hard-to-close wounds, according to published reports, including some 15% of diabetic foot ulcers in the U.S. that eventually required amputations are creating a compelling product offering for healthcare professionals treating the 900,000 diabetic foot ulcers each year!
Wound Care Is "Big Business" Both large pharmaceutical companies and device companies have realized that wound care is big business, For example, wound bandages and dressings are a $2 billion business in the USA, he said. Smith & Nephew and Johnson & Johnson have been among the first major pharmaceutical companies to recognise the potential of the wound care market
The global wound care market is expected to reach USD 20.4 Billion by 2021 from USD 17.0 Billion in 2016, growing at a CAGR of 3.6% from 2016 to 2021.
The advanced wound management product segment commanded the largest share in 2015, and is forecast to be the fastest-growing segment in the wound care market. Factors such as rising awareness regarding new technologies for wound care, government support in the form of funding, and rising diabetic and aging population are driving the growth of the wound care market.
The prominent players in the wound care market are 3M Company (U.S.), Baxter International, Inc. (U.S.), Coloplast A/S (Denmark.), Convatec Healthcare B.S.A.R.L (U.S.), Covidien PLC (Ireland), Derma Sciences, Inc. (U.S.), Ethicon, Inc. (U.S.), Hollister, Inc. (U.S.), Kinetic Concept, Inc. (U.S.), Mölnlycke Health Care (Sweden), and Smith & Nephew (U.K.).
MORE ABOUT Lescarden Inc. (LCAR)
Lescarden Incorporated is a biotechnology company dedicated to the research and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, autoimmune and cancer applications!
Years of product testing and refinement has led to the creation of Lescarden’s proprietary formula for purifying bovine cartilage producing a sterile white powder that optimizes the healing and anti-inflammatory processes. Today, the company’s exclusive bovine cartilage powder, marketed as Catrix®, is FDA and EU approved for the management of chronic wounds and severe burns.
Clinical and laboratory studies point to Catrix as a potential agent for the treatment of certain cancers.
The cornerstone of the Catrix product line, Catrix Wound Dressing is renowned for its superior healing characteristics.
Catrix Wound Dressing is a natural, biodegradable product, made from a specially processed bovine cartilage in the form of a fine white powder. Catrix has no chemical additives.
When applied directly to non-healing wounds, such as debubitus ulcers (bedsores), diabetic ulcers, and venous ulcers, Catrix Wound Dressing actually accelerates the healing process, effectively closing the wounds while minimizing scarring.
In studies performed on wounds that had previously failed to respond to months of standard wound healing treatment, dramatic improvements were seen in just seven weeks!
FDA-cleared for multiple healing applications
Catrix Wound Dressing is cleared for use by the Food and Drug Administration and is EU-certified for the management of:
Pressure ulcers (stages I-IV)
Stasis ulcers
1st and 2nd degree burns
Diabetic ulcers
Post-surgical incisions
Radiation dermatitis
Cuts, abrasions and irritations
Partial thickness wounds
Skin conditions associated with peristomal care
How Catrix Wound Dressing works
The unique properties Catrix Wound Dressing work with the body’s own healing capabilities to effectively close wounds. Catrix stimulates granulation within the wound, establishing a matrix that induces the development of the necessary components (connective tissue, skin, blood vessels) needed to heal. Containing 50% micronized collagen, Catrix Wound Dressing accelerates the biological process of reparation by activating the following processes:
Attracts fibroblasts – encourages production of connective tissue
Activates macrophages – stimulates formation of blood vessels
Stimulates growth of fibroblastes (12%) and keratinocytes (40%)
Stimulates growth fibroblasts and keratinocytes
Increases scar strength (resistance of the wound to tearing) by 50%
The result is a wound that heals rapidly, displays better quality of granulation and vascularization tissue, and a scar that is more aesthetic with superior tensile strength at every stage of its
subsequent recovery.
Advantages of Catrix Wound Dressing
Biodegradable - does not need to be removed from the wound
Completely absorbed at seven days
Compatible with gauzes and with moist applications
Can absorb exudate up to 10 times its weight
Controls excess exudates. Keeps the bed of the wound moist
Has a barrier effect – protects against infection
Does not harm the skin around the ulcer
Application is painless
Reduces bleeding
Has no adverse effects
Good for patients and the healthcare system
Catrix Wound Dressing offers important benefits to patients and healthcare providers:
Accelerated healing of wounds - leads to increased patient comfort, improved quality of life, and reduced chance of accidental infection
Decreased treatment cost - dramatic savings through reduced staff required to treat wounds, lower material cost per treatment, and shortened term of treatment required for full recovery
Simple, convenient application available in single-use foil packets - Catrix Wound Dressing is sprinkled directly from the packet onto the wound - makes it ideal for use in hospitals, extended care facilities and at-home care
Catrix Wound Dressing is packaged in cartons of 14 and 7, one-gram foil packets.
SUMMARY
Now is the time to buy shares of Lescarden (LCAR) BEFORE it gets acquired by a Smith and Nephew.
LCAR is ridiculously undervalued having an FDA and EU approved, patented and commercialized WOUND CARE product that is incredibly effective!
